Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis&lt;SUBTITLE&gt;A Randomized Controlled Trial&lt;/SUBTITLE&gt;

Harris, Steven T.

doi:10.1001/jama.282.14.1344

Cited by 2,252 publications

(1,499 citation statements)

References 30 publications

Supporting

Mentioning

1,356

Contrasting

Unclassified

Order By: Relevance

“…Another limitation is that the present study did not include a control group. Antifracture trials show that treatment with calcium and vitamin D alone has a mild antiresportive effect, (2)(3)(4)6,7) and it is possible that this may have slightly blunted the anabolic effects of teriparatide reported in the present study.…”

Section: Discussionmentioning

confidence: 62%

“…(1)(2)(3)(4)(5)(6)(7)(8) Generally, these can be divided into two types: (1) antiresorptive treatments such as bisphosphonates (1,2,4,6,7) that bring about a prompt decrease in biochemical markers of bone resorption followed a few months later by a reduction in bone formation markers (9) and (2) anabolic agents (currently only parathyroid hormone) (5,10) that bring about a prompt increase in bone formation followed a few weeks later by an increase in bone resorption. (11) Many modern treatments for osteoporosis have a profound effect on bone remodeling, and studies of bone turnover have an important role in the evaluation of their effect on bone quality.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Frost

Siddique

Blake

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Teriparatide increases skeletal mass, bone turnover markers, and bone strength, but local effects on bone tissue may vary between skeletal sites. We used positron emission tomography (PET) to study 18 F-fluoride plasma clearance (K i ) at the spine and standardized uptake values (SUVs) at the spine, pelvis, total hip, and femoral shaft in 18 postmenopausal women with osteoporosis. Subjects underwent a 1-hour dynamic scan of the lumbar spine and a 10-minute static scan of the pelvis and femurs at baseline and after 6 months of treatment with 20 mg/day teriparatide. Blood samples were taken to derive the arterial input function and lumbar spine K i values evaluated using a three-compartment model. SUVs were calculated for the spine, pelvis, total hip, and femoral shaft. After 6 months treatment with teriparatide, spine K i values increased by 24% (p ¼ .0003), while other model parameters were unchanged except for the fraction of tracer going to bone mineral (k 3 /[k 2 þ k 3 ]), which increased by 23% (p ¼ .0006). In contrast to K i , spine SUVs increased by only 3% (p ¼ .84). The discrepancy between changes in K i and SUVs was explained by a 20% decrease in 18 F À plasma concentration. SUVs increased by 37% at the femoral shaft (p ¼ .0019), 20% at the total hip (p ¼ .032), and 11% at the pelvis (p ¼ .070). Changes in bone turnover markers and BMD were consistent with previous trials. We conclude that the changes in bone formation rate during teriparatide treatment as measured by 18 F À PET differ at different skeletal sites, with larger increases in cortical bone than at trabecular sites. ß

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Frost

Siddique

Blake

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…Osteoporotic fractures were counted as events beginning after completing month 6 because fracture rates in treated and untreated patients begin to diverge between treatment and placebo arms in the first 6-12 months in randomized trials of oral bisphosphonates [20,21]. In contrast, to allow adequate time for BMD response to oral bisphosphonates, post-index BMD measurements were counted only from the beginning of month 13 onwards (i.e.…”

Section: Outcome Definitionsmentioning

confidence: 99%

Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates

Imel

Eckert

Modi

et al. 2016

Bone

View full text Add to dashboard Cite

show abstract

“…However, the changes in BMD explain only a fraction of the observed fracture risk reduction [5][6][7]. These observations suggest that anti-resorptive agents improve bone strength by decreasing bone turnover and by increasing intrinsic material properties of bone rather than simply affecting bone mass.…”

Section: Introductionmentioning

confidence: 98%

The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength

Yao

Cheng

Koester

et al. 2007

Bone

View full text Add to dashboard Cite

The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this Study, 18 month Fischer 344 rats were ovariectomized and treated with a single dose of risedronate (intravenous, iv, 500μg), zoledronic acid (iv, 100μg) or continuous raloxifene (2mg/ kg, po., 3x/wk). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle x-ray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength. lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene.

show abstract

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Abstract: These data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.

Cited by 2,252 publications

References 30 publications

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates

The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength

Contact Info

Product

Resources

About